Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:HALO
  • CUSIP: 40637H10
  • Web: www.halozyme.com
Capitalization:
  • Market Cap: $1.6 billion
  • Outstanding Shares: 128,615,000
Average Prices:
  • 50 Day Moving Avg: $13.45
  • 200 Day Moving Avg: $12.58
  • 52 Week Range: $7.70 - $15.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.32
  • P/E Growth: -0.23
Sales & Book Value:
  • Annual Revenue: $133.76 million
  • Price / Sales: 11.93
  • Book Value: ($0.46) per share
  • Price / Book: -26.98
Profitability:
  • EBIDTA: ($92,040,000.00)
  • Net Margins: -44.60%
  • Return on Equity: -405.28%
  • Return on Assets: -26.67%
Debt:
  • Debt-to-Equity Ratio: -16.66%
  • Current Ratio: 5.18%
  • Quick Ratio: 4.93%
Misc:
  • Average Volume: 1.28 million shs.
  • Beta: 2.27
  • Short Ratio: 18.3
 

Frequently Asked Questions for Halozyme Therapeutics (NASDAQ:HALO)

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. The company had revenue of $29.60 million for the quarter, compared to analyst estimates of $30.79 million. Halozyme Therapeutics had a negative return on equity of 405.28% and a negative net margin of 44.60%. The company's revenue for the quarter was down 30.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.16) EPS. View Halozyme Therapeutics' Earnings History.

Where is Halozyme Therapeutics' stock going? Where will Halozyme Therapeutics' stock price be in 2017?

7 equities research analysts have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $6.75 to $20.00. On average, they expect Halozyme Therapeutics' stock price to reach $13.79 in the next year. View Analyst Ratings for Halozyme Therapeutics.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 24,828,851 shares, an increase of 0.2% from the April 28th total of 24,768,116 shares. Based on an average daily volume of 843,826 shares, the days-to-cover ratio is currently 29.4 days. Approximately 22.8% of the company's stock are sold short.

Who are some of Halozyme Therapeutics' key competitors?

Who owns Halozyme Therapeutics stock?

Halozyme Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Third Security LLC (15.06%), BlackRock Inc. (8.63%), Iridian Asset Management LLC CT (8.11%), Vanguard Group Inc. (6.84%), BB Biotech AG (6.05%) and First Eagle Investment Management LLC (5.77%). Company insiders that own Halozyme Therapeutics stock include Kenneth J Kelley and Laurie Stelzer. View Institutional Ownership Trends for Halozyme Therapeutics.

Who sold Halozyme Therapeutics stock? Who is selling Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, Iridian Asset Management LLC CT, First Eagle Investment Management LLC, State Street Corp, Candriam Luxembourg S.C.A., Oxford Asset Management and Morgan Stanley. View Insider Buying and Selling for Halozyme Therapeutics.

Who bought Halozyme Therapeutics stock? Who is buying Halozyme Therapeutics stock?

Halozyme Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Pictet Asset Management Ltd., Artisan Partners Limited Partnership, Bank of New York Mellon Corp, Vanguard Group Inc., Endurant Capital Management LP, Snyder Capital Management L P and JPMorgan Chase & Co.. View Insider Buying and Selling for Halozyme Therapeutics.

How do I buy Halozyme Therapeutics stock?

Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Halozyme Therapeutics stock cost?

One share of Halozyme Therapeutics stock can currently be purchased for approximately $12.41.

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $13.79 (11.13% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/17/2017BMO Capital MarketsInitiated CoverageMarket Perform$14.00LowView Rating Details
3/30/2017Deutsche Bank AGBoost Price TargetBuy$15.00 -> $17.00LowView Rating Details
1/23/2017Piper Jaffray CompaniesReiterated RatingBuy$20.00N/AView Rating Details
1/6/2017Citigroup IncDowngradeBuy -> NeutralN/AView Rating Details
11/8/2016Jefferies Group LLCReiterated RatingSell$6.75N/AView Rating Details
9/8/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00N/AView Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$27.00 -> $16.00N/AView Rating Details
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00N/AView Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$20.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Earnings History by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.25)($0.26)$30.79 million$29.60 millionViewListenView Earnings Details
2/28/2017Q416($0.30)($0.21)$37.94 million$39.00 millionViewListenView Earnings Details
11/7/2016Q316($0.27)($0.23)$34.43 million$31.90 millionViewListenView Earnings Details
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.18)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
2017 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.27)($0.27)($0.27)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.28)($0.28)($0.28)
Q4 20171($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Halozyme Therapeutics (NASDAQ:HALO)
Insider Ownership Percentage: 16.60%
Institutional Ownership Percentage: 82.94%
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Insider Trades by Quarter for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Halozyme Therapeutics (NASDAQ:HALO)
Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
Source:
DateHeadline
americanbankingnews.com logoZacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) Will Announce Quarterly Sales of $33.11 Million
www.americanbankingnews.com - May 26 at 11:57 AM
americanbankingnews.com logoZacks: Brokerages Expect Halozyme Therapeutics, Inc. (HALO) to Post -$0.25 EPS
www.americanbankingnews.com - May 25 at 12:20 AM
prnewswire.com logoHalozyme Therapeutics Announces Completion Of Public Offering And Full ...
www.prnewswire.com - May 24 at 5:28 PM
finance.yahoo.com logoHalozyme Therapeutics Announces Completion Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
finance.yahoo.com - May 24 at 5:28 PM
seekingalpha.com logoHalozyme: PEGPH20 Clinical Development Progress Does Not Yet Translate To Value
seekingalpha.com - May 23 at 5:12 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May 22, 2017
finance.yahoo.com - May 22 at 11:09 AM
streetinsider.com logoHalozyme Therapeutics (HALO) Prices 10M Share Offering at $12.50/Sh
www.streetinsider.com - May 20 at 10:31 PM
nasdaq.com logoMid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge - Nasdaq
www.nasdaq.com - May 19 at 10:24 PM
fool.com logoHalozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% - Motley Fool
www.fool.com - May 19 at 10:24 PM
nasdaq.com logoHalozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10%
www.nasdaq.com - May 19 at 5:23 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10%
finance.yahoo.com - May 19 at 5:22 PM
finance.yahoo.com logoWhy Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today
finance.yahoo.com - May 19 at 5:22 PM
investorplace.com logoWhy Foot Locker, Inc. (FL), Campbell Soup Company (CPB) and Halozyme Therapeutics, Inc. (HALO) Are 3 of Today’s Worst Stocks
investorplace.com - May 19 at 4:55 PM
investorplace.com logoWhy Foot Locker, Inc. (FL), Campbell Soup Company (CPB) and Halozyme Therapeutics, Inc. (HALO) Are 3 of Today’s Worst Stocks
investorplace.com - May 19 at 4:51 PM
finance.yahoo.com logoHalozyme Therapeutics Announces Public Offering Of Common Stock
finance.yahoo.com - May 19 at 10:07 AM
finance.yahoo.com logoHalozyme shares fall after secondary share offering annoucned
finance.yahoo.com - May 19 at 10:07 AM
finance.yahoo.com logoHalozyme Therapeutics Prices Public Offering Of Common Stock
finance.yahoo.com - May 19 at 10:07 AM
finance.yahoo.com logoBiotech Movers: Lion Biotechnologies, XBiotech, Halozyme
finance.yahoo.com - May 19 at 10:07 AM
finance.yahoo.com logoBlog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results
finance.yahoo.com - May 18 at 9:44 AM
prnewswire.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO - PR Newswire (press release)
www.prnewswire.com - May 17 at 10:35 PM
finance.yahoo.com logoHalozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO
finance.yahoo.com - May 17 at 5:35 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - May 12 at 11:20 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 12 at 6:42 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 12:27 AM
reuters.com logoBRIEF-Halozyme reports first quarter 2017 financial results
www.reuters.com - May 10 at 12:23 PM
seekingalpha.com logoHalozyme Therapeutics, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 10 at 12:23 PM
finance.yahoo.com logoHalozyme Therapeutics reports 1Q loss
finance.yahoo.com - May 10 at 12:22 PM
finance.yahoo.com logoEdited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 12:22 PM
finance.yahoo.com logoHalozyme Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 5:23 PM
finance.yahoo.com logoInvestor Network: Halozyme Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 12:43 PM
seekingalpha.com logoHalozyme Banks On Pancreatic Cancer Treatment, Study Progresses Strongly - Seeking Alpha
seekingalpha.com - May 4 at 5:47 PM
seekingalpha.com logoHalozyme Banks On Pancreatic Cancer Treatment, Study Progresses Strongly - Seeking Alpha
seekingalpha.com - May 4 at 5:47 PM
americanbankingnews.com logoSomewhat Favorable Media Coverage Very Likely to Impact Halozyme Therapeutics (HALO) Share Price
www.americanbankingnews.com - May 3 at 8:58 PM
americanbankingnews.com logo$31.5 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter
www.americanbankingnews.com - May 3 at 1:01 PM
americanbankingnews.com logo Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) Will Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - May 1 at 11:02 PM
americanbankingnews.com logoHalozyme Therapeutics (HALO) Earns News Impact Rating of -0.12
www.americanbankingnews.com - April 30 at 11:39 AM
americanbankingnews.com logoHalozyme Therapeutics (HALO) Earns Daily News Impact Score of 0.21
www.americanbankingnews.com - April 26 at 10:40 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. – Value Analysis (NASDAQ:HALO) : April 24, 2017
finance.yahoo.com - April 24 at 5:20 PM
americanbankingnews.com logoHalozyme Therapeutics (HALO) Earning Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 10:25 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April 21, 2017
finance.yahoo.com - April 21 at 11:10 AM
americanbankingnews.com logoHalozyme Therapeutics (HALO) Receives Daily News Impact Score of 0.05
www.americanbankingnews.com - April 17 at 10:17 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 17 at 6:37 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Coverage Initiated by Analysts at BMO Capital Markets
www.americanbankingnews.com - April 17 at 9:21 AM
americanbankingnews.com logoHalozyme Therapeutics (HALO) Earns News Sentiment Rating of -0.06
www.americanbankingnews.com - April 14 at 3:26 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 10 at 10:57 PM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - April 10 at 6:07 PM
finance.yahoo.com logoHalozyme To Host First Quarter 2017 Financial Results Conference Call
finance.yahoo.com - April 10 at 5:21 PM
finance.yahoo.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April 6, 2017
finance.yahoo.com - April 7 at 10:11 AM
americanbankingnews.com logoHalozyme Therapeutics, Inc. (HALO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:37 AM
reuters.com logoBRIEF-Halozyme's PEGPH20 increases immune response, effectiveness of immunotherapies in preclinical cancer models
www.reuters.com - April 3 at 1:05 PM

Social

Chart

Halozyme Therapeutics (HALO) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff